# Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Source: https://onco.cc/trials/nct06401824/  
OnCo record `nct06401824` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of bevacizumab in lung cancer, run by Maastricht University Medical Center, now recruiting.

## Summary

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases is a phase 2, interventional study registered as NCT06401824 by Maastricht University Medical Center, with a registry enrolment figure of 25 participants, started 2025-04-24 and due to reach its primary completion in 2026-11-01. Interventions recorded: Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab. Conditions listed: NSCLC Stage IV; Brain Metastases, Adult. Primary outcome: brain metastases overall response rate (ORR). Lung eligibility wording from the registry: "Pathology proven metastatic non-squamous NSCLC". Sites: Netherlands. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06401824
- Phase: 2
- Setting: A Single Arm Phase II Study Evaluating Intracranial Efficacy of Sacituzumab Govitecan (SG) With Bevacizumab in Patients With Active, Asymptomatic Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
- Sponsor: Maastricht University Medical Center
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT06401824: https://clinicaltrials.gov/study/NCT06401824

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06401824.json